formoterol
Sign in to saveFormoterol, also known as eformoterol, is a long-acting β2 agonist (LABA) used as a bronchodilator in the management of asthma and chronic obstructive pulmonary disease (COPD). Formoterol has an extended duration of action (up to 12 h) compared to short-acting β2 agonists such as salbutamol (albuterol), which are effective for 4 h to 6 h. Formoterol has a relatively rapid onset of action compared to other LABAs, and is effective within 2-3 minutes. The 2022 Global Initiative for Asthma report recommends a combination formoterol/inhaled corticosteroid inhaler as both a preve
Key facts
- Drug.verifiedrevid
- 461113044
- Drug.caption2
- Above (R,R)-(−)-formoterol Below (S,S)-(+)-formoterol
- Drug.image
- Formoterol.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 230
- Drug.image2
- Formoterol ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.caption
- Formoterol molecular structure
- Drug.chirality
- Racemic mixture
- Drug.tradename
- Oxeze, Foradil, Symbicort, others
- Drug.pregnancy_AU
- B3
- Drug.licence_EU
- yes
- Drug.INN_EMA
- formoterol fumarate dihydrate
- Drug.legal_AU
- S4
- Drug.legal_NZ
- Prescription only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Article
6 sectionsContents
- Side effects
- Mechanism of action
- Society and culture
- Brand names
- Uses and combinations
- References
Formoterol, also known as eformoterol, is a long-acting β2 agonist (LABA) used as a bronchodilator in the management of asthma and chronic obstructive pulmonary disease (COPD). Formoterol has an extended duration of action (up to 12 h) compared to short-acting β2 agonists such as salbutamol (albuterol), which are effective for 4 h to 6 h. Formoterol has a relatively rapid onset of action compared to other LABAs, and is effective within 2-3 minutes. The 2022 Global Initiative for Asthma report recommends a combination formoterol/inhaled corticosteroid inhaler as both a preventer and reliever treatment for asthma in adults. In children, a short-acting β2 adrenergic agonist (e.g., salbutamol) is still recommended.
It was patented in 1972 and came into medical use in 1998. It is available as a generic medication. It is also marketed in the combination formulations budesonide/formoterol and mometasone/formoterol.
Gallery (2)
Connections
Categories
4-Methoxyphenyl compoundsBeta2-adrenergic agonistsChemical articles with multiple PubChem CIDsDrug has EMA linkDrugs developed by AstraZenecaDrugs developed by Merck & Co.Drugs developed by NovartisDrugs developed by Schering-PloughDrugs with non-standard legal statusECHA InfoCard ID from WikidataFormamidesMultiple chemicals in an infobox that need indexing